Despite Innovative Pharmaceutical Biotech now being profitable, shareholder earnings are diluted. Unusual items raise concern as they may be one-offs and not show the true earnings of the company. Potential investors are advised to fully understand the risks and remember the importance of earnings per share in assessing share price growth potential.
領航醫藥生物科技股票討論區
暫無評論